Tenaya Therapeutics Inc
TNYA
NASDAQ
Biotechnology
$0.73
USD
0.00 (-0.67%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $164.36M
Volume 1.5M
Revenue
$1.33M
TTM
— YoY
Gross Margin
100%
TTM
— YoY
Net Income
$-103.11M
TTM
-3.5%
YoY
Operating Cash Flow
$-52.33M
TTM
+32.0%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.2 | 1.1 |
YoY Growth | — | — | — | — | — |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.2 | 1.1 |
Selling, General & Administrative | 6.7 | 5.6 | 6.0 | 5.4 | 5.4 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 21.8 |
Total Operating Expenses | 24.1 | 20.9 | 20.8 | 20.3 | 43.8 |
Operating Income | -24.1 | -20.9 | -20.8 | -20.1 | -42.7 |
EBITDA | -22.0 | -19.1 | -18.9 | -18.3 | -19.2 |
Other Income / Expense | -0.0 | 0.0 | 0.0 | 0.0 | -1.4 |
Total Other Income / Expense | 0.8 | 0.7 | 0.6 | 0.8 | -0.7 |
Income Before Income Taxes | -23.3 | -20.3 | -20.2 | -19.3 | -43.4 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -23.3 | -20.3 | -20.2 | -19.3 | -43.4 |
Consolidated Net Income / Loss | -23.3 | -20.3 | -20.2 | -19.3 | -43.4 |
Net Income Attributable to Common Shareholders | -23.3 | -20.3 | -20.2 | -19.3 | -43.4 |
Basic EPS | -$0.14 | -$0.12 | -$0.11 | -$0.09 | -$0.20 |
Diluted EPS | -$0.14 | -$0.12 | -$0.11 | -$0.09 | -$0.20 |
Basic Shares Outstanding | 162.8M | 163.3M | 175.9M | 216.9M | 217.6M |
Diluted Shares Outstanding | 162.8M | 163.3M | 175.9M | 216.9M | 217.6M |